. 2019 Sep 3;20(17):4307. doi: 10.3390/ijms20174307

Table 5.

Clinical studies applying CIK cells for the treatment of hematological diseases.

Study Reference	RCTs (n) Total	Patients (n) Total	Therapy	CR	PR	ORR	DCR	PD
Wang et al., 2017, [81]	12	594	Chemotherapy;	OR = 2.71 CI = 1.60–4.58 p = 0.0002	OR = 1.49 CI = 1.01–2.20 p = 0.04	OR = 2.77 CI = 1.88–4.10 p < 0.00001	OR = 2.90 CI = 1.72–4.90 p < 0.0001	OR = 0.34 CI = 0.20–0.58 p < 0.0001
Wang et al., 2017, [81]	12	594	Immunotherapy group: additional CIK cell and DC cell transfusions	OR = 2.71 CI = 1.60–4.58 p = 0.0002	OR = 1.49 CI = 1.01–2.20 p = 0.04	OR = 2.77 CI = 1.88–4.10 p < 0.00001	OR = 2.90 CI = 1.72–4.90 p < 0.0001	OR = 0.34 CI = 0.20–0.58 p < 0.0001
Bader, 2016, [82]	1	40	Chemotherapy;	n.a	n.a	n.a.	n.a.	n.a.
Bader, 2016, [82]	1	40	Immunotherapy group: additional IL-15 activated CIK cell transfusions	n.a	n.a	n.a.	n.a.	n.a.
Total	13	634

n.a., not available; OR = odd ratio; CI = coefficient of interference.